178 related articles for article (PubMed ID: 38129848)
1. Circulating small extracellular vesicles microRNAs plus CA-125 for treatment stratification in advanced ovarian cancer.
Zhou X; Liu M; Sun L; Cao Y; Tan S; Luo G; Liu T; Yao Y; Xiao W; Wan Z; Tang J
J Transl Med; 2023 Dec; 21(1):927. PubMed ID: 38129848
[TBL] [Abstract][Full Text] [Related]
2. miRNAs derived from circulating small extracellular vesicles as diagnostic biomarkers for nasopharyngeal carcinoma.
Jiang L; Zhang Y; Li B; Kang M; Yang Z; Lin C; Hu K; Wei Z; Xu M; Mi J; Wang R; Wu F
Cancer Sci; 2021 Jun; 112(6):2393-2404. PubMed ID: 33728743
[TBL] [Abstract][Full Text] [Related]
3. A study of clinicopathologic factors as indicators for early prediction of suboptimal debulking surgery after neoadjuvant chemotherapy in advanced ovarian cancer.
Son JH; Chang K; Kong TW; Paek J; Chang SJ; Ryu HS
J Obstet Gynaecol Res; 2018 Jul; 44(7):1294-1301. PubMed ID: 29683235
[TBL] [Abstract][Full Text] [Related]
4. A New Approach for Prostate Cancer Diagnosis by miRNA Profiling of Prostate-Derived Plasma Small Extracellular Vesicles.
Zabegina L; Nazarova I; Nikiforova N; Slyusarenko M; Sidina E; Knyazeva M; Tsyrlina E; Novikov S; Reva S; Malek A
Cells; 2021 Sep; 10(9):. PubMed ID: 34572021
[TBL] [Abstract][Full Text] [Related]
5. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
Bryant A; Hiu S; Kunonga PT; Gajjar K; Craig D; Vale L; Winter-Roach BA; Elattar A; Naik R
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015048. PubMed ID: 36161421
[TBL] [Abstract][Full Text] [Related]
6. Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy.
Lyons YA; Reyes HD; McDonald ME; Newtson A; Devor E; Bender DP; Goodheart MJ; Gonzalez Bosquet J
Int J Gynecol Cancer; 2020 Jun; 30(6):845-852. PubMed ID: 32341114
[TBL] [Abstract][Full Text] [Related]
7. Nadir CA-125 serum levels during neoadjuvant chemotherapy and no residual tumor at interval debulking surgery predict prognosis in advanced stage ovarian cancer.
Nakamura K; Kitahara Y; Nishimura T; Yamashita S; Kigure K; Ito I; Kanuma T
World J Surg Oncol; 2020 Aug; 18(1):200. PubMed ID: 32791996
[TBL] [Abstract][Full Text] [Related]
8. Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies.
Petrillo M; Zannoni GF; Beltrame L; Martinelli E; DiFeo A; Paracchini L; Craparotta I; Mannarino L; Vizzielli G; Scambia G; D'Incalci M; Romualdi C; Marchini S
Ann Oncol; 2016 Apr; 27(4):625-34. PubMed ID: 26782955
[TBL] [Abstract][Full Text] [Related]
9. Two microRNAs of plasma-derived small extracellular vesicles as biomarkers for metastatic non-small cell lung cancer.
Geng N; Qi Y; Qin W; Li S; Jin H; Jiang Y; Wang X; Wei S; Wang P
BMC Pulm Med; 2023 Jul; 23(1):259. PubMed ID: 37452310
[TBL] [Abstract][Full Text] [Related]
10. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
[TBL] [Abstract][Full Text] [Related]
11. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850).
Fagotti A; Ferrandina MG; Vizzielli G; Pasciuto T; Fanfani F; Gallotta V; Margariti PA; Chiantera V; Costantini B; Gueli Alletti S; Cosentino F; Scambia G
Int J Gynecol Cancer; 2020 Nov; 30(11):1657-1664. PubMed ID: 33028623
[TBL] [Abstract][Full Text] [Related]
12. Diffusion-Weighted Magnetic Resonance Imaging and Morphological Characteristics Evaluation for Outcome Prediction of Primary Debulking Surgery for Advanced High-Grade Serous Ovarian Carcinoma.
Li H; Lu J; Deng L; Guo Q; Lin Z; Zhao S; Ge H; Qiang J; Gu Y; Liu Z
J Magn Reson Imaging; 2023 May; 57(5):1340-1349. PubMed ID: 36054024
[TBL] [Abstract][Full Text] [Related]
13. Identification and evaluation of circulating small extracellular vesicle microRNAs as diagnostic biomarkers for patients with indeterminate pulmonary nodules.
Zheng D; Zhu Y; Zhang J; Zhang W; Wang H; Chen H; Wu C; Ni J; Xu X; Nian B; Chen S; Wang B; Li X; Zhang Y; Zhang J; Zhong W; Xiong L; Li F; Zhang D; Xu J; Jiang G
J Nanobiotechnology; 2022 Apr; 20(1):172. PubMed ID: 35366907
[TBL] [Abstract][Full Text] [Related]
14. Role of delayed interval debulking for persistent residual disease after more than 5 cycles of chemotherapy for primary advanced ovarian cancer. An international multicenter study.
Plett H; Filippova OT; Garbi A; Kommoss S; Rosendahl M; Langstraat C; Phadnis S; Muallem MZ; Baert T; Chi DS; Aletti GD; Taran FA; Ramspott JP; Zivanovic O; du Bois A; Sonoda Y; Gardner G; Traut A; Roche KL; Harter P
Gynecol Oncol; 2020 Nov; 159(2):434-441. PubMed ID: 32919778
[TBL] [Abstract][Full Text] [Related]
15. Small Extracellular Vesicles from adipose-derived stem cells suppress cell proliferation by delivering the let-7 family of microRNAs in ovarian cancer.
Suzuki H; Yokoi A; Uno K; Yoshida K; Kitagawa M; Asano-Inami E; Matsuo S; Nagao Y; Suzuki K; Nakamura K; Yoshihara M; Tamauchi S; Shimizu Y; Ikeda Y; Yoshikawa N; Kajiyama H; Yamamoto Y
Biochem Biophys Res Commun; 2023 Nov; 680():211-219. PubMed ID: 37782986
[TBL] [Abstract][Full Text] [Related]
16. Seminal extracellular vesicle sncRNA sequencing reveals altered miRNA/isomiR profiles as sperm retrieval biomarkers for azoospermia.
Larriba S; Sánchez-Herrero JF; Pluvinet R; López-Rodrigo O; Bassas L; Sumoy L
Andrology; 2024 Jan; 12(1):137-156. PubMed ID: 37245055
[TBL] [Abstract][Full Text] [Related]
17. Clinical relevance of circulating cell-free microRNAs in ovarian cancer.
Nakamura K; Sawada K; Yoshimura A; Kinose Y; Nakatsuka E; Kimura T
Mol Cancer; 2016 Jun; 15(1):48. PubMed ID: 27343009
[TBL] [Abstract][Full Text] [Related]
18. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E
Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049
[TBL] [Abstract][Full Text] [Related]
19. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer.
Petrillo M; Zannoni GF; Tortorella L; Pedone Anchora L; Salutari V; Ercoli A; Margariti PA; Scambia G; Fagotti A
Am J Obstet Gynecol; 2014 Dec; 211(6):632.e1-8. PubMed ID: 24954656
[TBL] [Abstract][Full Text] [Related]
20. Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
Yao SE; Tripcony L; Sanday K; Robertson J; Perrin L; Chetty N; Land R; Garrett A; Obermair A; Nascimento M; Tang A; Jagasia N; Singh P; Nicklin J
Int J Gynecol Cancer; 2020 Dec; 30(12):1935-1942. PubMed ID: 33122245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
